Available EXPANDED_ACCESS NCT01317953

Oral Green Tea Extract for Small Cell Lung Cancer

Phase ⅠStudy of Oral Green Tea Extract as Maintenance Therapy for Extensive-stage Small Cell Lung Cancer

Sponsor: Shandong Cancer Hospital and Institute

Updated 7 times since 2017 Last updated: Apr 3, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01317953, this observational or N/A phase trial focuses on Small Cell Lung Carcinoma and remains ongoing. Sponsored by Shandong Cancer Hospital and Institute, it has been updated 7 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Jan 2021 — Jul 2024 [monthly]

Available
May 2019 — Jan 2021 [monthly]

Available
Jun 2018 — May 2019 [monthly]

Available

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Available

Status: Recruiting → Available · Phase: PHASE1 → None
Jan 2017 — Apr 2018 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Cancer Hospital and Institute

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China